3 results
Approved WMORecruiting
To assess the efficacy and safety of LCI699 in CD patients
Approved WMOCompleted
The purpose of this studie is to evaluate the bioequivalence of canagliflozin.
Approved WMOCompleted
To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…